GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor TIM-3, after its cobolimab candidate flunked a phase 3 trial in lung cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback